DB18675InvestigationalProtein Based Therapies
Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
- Mechanism
- Curator reviewed
Pharmacologically active on Tumor necrosis factor receptor superfamily member 10B
- Also known as
- Immunoglobulin, anti-(human death receptor 5) (human-Lama glama clone IF5 single-domain VHH fragment) fusion protein with peptide linker (GGS)2 fusion protein with immunoglobulin anti-(human death receptor 5) (human-Lama glama clone IF5 single-domain VHH · Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5).
- Code names
- INBRX-109
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Ozekibart, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account